IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 219 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $142,388 | +2.4% | 31,294 | +58.4% | 0.00% | -100.0% |
| Q2 2023 | $139,047 | +8.5% | 19,751 | -5.9% | 0.00% | – |
| Q1 2023 | $128,212 | -13.5% | 20,984 | -9.5% | 0.00% | – |
| Q4 2022 | $148,197 | -17.7% | 23,192 | +23.5% | 0.00% | – |
| Q3 2022 | $180,000 | -10.9% | 18,782 | +2.5% | 0.00% | -100.0% |
| Q2 2022 | $202,000 | -9.8% | 18,324 | +36.1% | 0.00% | – |
| Q1 2022 | $224,000 | -10.4% | 13,468 | +2.8% | 0.00% | -100.0% |
| Q4 2021 | $250,000 | -38.9% | 13,099 | -21.1% | 0.00% | 0.0% |
| Q3 2021 | $409,000 | -5.8% | 16,600 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $434,000 | +9.0% | 16,679 | +32.7% | 0.00% | 0.0% |
| Q1 2021 | $398,000 | -31.0% | 12,568 | +1.1% | 0.00% | -50.0% |
| Q4 2020 | $577,000 | +9.3% | 12,432 | -22.5% | 0.00% | 0.0% |
| Q3 2020 | $528,000 | +21.1% | 16,034 | +0.9% | 0.00% | 0.0% |
| Q2 2020 | $436,000 | +43.9% | 15,896 | +57.2% | 0.00% | 0.0% |
| Q1 2020 | $303,000 | – | 10,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MHR Fund Management | 11,997,103 | $84,459,605 | 11.88% |
| MPM BioImpact LLC | 2,950,118 | $20,768,831 | 4.18% |
| Perceptive Advisors | 14,036,410 | $98,816,326 | 2.86% |
| Velan Capital Investment Management LP | 240,000 | $1,689,600 | 1.57% |
| Parametrica Management Ltd | 96,500 | $679,360 | 1.31% |
| Boxer Capital, LLC | 3,705,133 | $26,084 | 1.21% |
| Soleus Capital Management, L.P. | 1,239,777 | $8,728,030 | 0.97% |
| Opaleye Management Inc. | 421,000 | $2,963,840 | 0.71% |
| 683 Capital Management, LLC | 1,400,000 | $9,856,000 | 0.71% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,758,759 | $12,381,665 | 0.70% |